Scilex Holding Company Increase (Decrease) in Accounts Payable, Trade
Scilex Holding Company (SCLX) reported Increase (Decrease) in Accounts Payable, Trade of $19.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-08-14
- Scilex Holding Company increase (decrease) in accounts payable, trade for the quarter ending 2026-06-30 was $3.78M, a 118.69% increase year-over-year.
- Scilex Holding Company increase (decrease) in accounts payable, trade for the quarter ending 2026-03-31 was $15.81M, a 208.35% increase year-over-year.
- Scilex Holding Company increase (decrease) in accounts payable, trade for the quarter ending 2025-12-31 was $1.77M, a 65.69% decline year-over-year.
- Scilex Holding Company increase (decrease) in accounts payable, trade for the quarter ending 2025-09-30 was $4.50M, a 178.80% increase year-over-year.
- Scilex Holding Company increase (decrease) in accounts payable, trade for fiscal 2025 was $13.12M, a 76.86% increase from fiscal 2024.
- Scilex Holding Company increase (decrease) in accounts payable, trade for fiscal 2024 was $7.42M, a 62.68% decline from fiscal 2023.
- Scilex Holding Company increase (decrease) in accounts payable, trade for fiscal 2023 was $19.88M, a 608.48% increase from fiscal 2022.
- Scilex Holding Company increase (decrease) in accounts payable, trade for fiscal 2022 was $2.81M.
| Period end | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $19.59M 10-Q · filed 2026-08-14 | $21.36M derived: sum of 3 quarters · filed 2026-08-14 | $25.86M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $15.81M 10-Q · filed 2026-05-20 | $17.58M derived: sum of 2 quarters · filed 2026-05-20 | $22.08M derived: sum of 3 quarters · filed 2026-05-20 | $23.80M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $6.26M derived: sum of 2 quarters · filed 2026-04-10 | $7.99M derived: sum of 3 quarters · filed 2026-08-14 | $13.12M 10-K · filed 2026-04-10 |
| 2025-09-30 | $4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $6.22M derived: sum of 2 quarters · filed 2026-08-14 | $11.35M 10-Q · filed 2025-11-14 | $16.51M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $6.86M 10-Q · filed 2026-08-14 | $12.01M derived: sum of 3 quarters · filed 2026-08-14 | $13.62M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $5.13M 10-Q · filed 2026-05-20 | $10.28M derived: sum of 2 quarters · filed 2026-05-20 | $11.89M derived: sum of 3 quarters · filed 2026-05-20 | $11.28M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $5.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $6.77M derived: sum of 2 quarters · filed 2026-04-10 | $6.15M derived: sum of 3 quarters · filed 2026-04-10 | $7.42M 10-K · filed 2026-04-10 |
| 2024-09-30 | $1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.00M derived: sum of 2 quarters · filed 2025-11-14 | $2.27M 10-Q · filed 2025-11-14 | $10.66M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$612.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $653.00K 10-Q · filed 2025-08-13 | $9.05M derived: sum of 3 quarters · filed 2025-08-13 | $16.20M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.26M 10-Q · filed 2025-05-14 | $9.66M derived: sum of 2 quarters · filed 2025-05-14 | $16.81M derived: sum of 3 quarters · filed 2025-05-14 | $19.14M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $8.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $15.55M derived: sum of 2 quarters · filed 2025-03-31 | $17.88M derived: sum of 3 quarters · filed 2025-03-31 | $19.88M 10-K · filed 2025-03-31 |
| 2023-09-30 | $7.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | $9.48M derived: sum of 2 quarters · filed 2025-01-17 | $11.49M 10-Q · filed 2025-01-17 | $11.32M derived: sum of 4 quarters · filed 2025-01-17 |
| 2023-06-30 | $2.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $4.33M 10-Q · filed 2024-08-13 | $4.17M derived: sum of 3 quarters · filed 2024-08-13 | $6.82M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $2.00M 10-Q · filed 2024-05-13 | $1.84M derived: sum of 2 quarters · filed 2024-05-13 | $4.48M derived: sum of 3 quarters · filed 2024-05-13 | $4.27M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$161.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $2.48M derived: sum of 2 quarters · filed 2024-03-12 | $2.27M derived: sum of 3 quarters · filed 2024-03-12 | $2.81M 10-K · filed 2024-03-12 |
| 2022-09-30 | $2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $2.43M derived: sum of 2 quarters · filed 2023-11-14 | $2.97M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$209.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $324.00K 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $533.00K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | -$3.84M 10-K · filed 2024-03-12 | |||
| 2020-12-31 | -$4.06M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |